Navigation Links
ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Metastatic Pancreatic Cancer
Date:5/19/2008

mental significance, not only in terms of basic pharmacology, but in establishing the physiological mechanisms-of-action that are of major importance in determining the predictability of a new anti-cancer agent, in establishing the optimal dose regimens for a given type of cancer, and ultimately in gaining regulatory approval for Rexin-G in the United States. Taken together with the results of previous studies, the current on-going Phase I/II study confirms the exemplary safety and therapeutic potential of Rexin-G, the first and so far only targeted gene delivery system shown to be safe and effective in the clinic.

For more information about Rexin-G, on-going clinical trials in the USA and abroad, and/or Epeius pathotropic (disease-seeking) gene delivery systems, please contact Dr. Erlinda M. Gordon at egordon@epeiusbiotech.com.

This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R). http://www.Send2Press.com


'/>"/>
SOURCE Epeius Biotechnologies
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Commencement 2008: Student innovation could improve data storage, magnetic sensors
2. The Diabetes Series 2008: Experts Speak About Developing Diabetes Therapeutics
3. Correction to Press Release Dated January 31, 2008: Inverness Medical Innovations to Participate at 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008
4. The World Economic Forum Announces Technology Pioneers 2008: Mondobiotech Selected
5. Oral PBI-1402 Demonstrates Significant Activity in Chemotherapy-Induced Anemia Phase II Clinical Trial
6. ANX-530 Demonstrates Equivalent Pharmacokinetics to Navelbine(R) in a Registrational Bioequivalence Clinical Study
7. Bringing a New Rhythm to Cardiology Workflow: Siemens Demonstrates Answers to Cardiologys Toughest Questions
8. 960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotechs Novel 5-FU Central Venous Catheter
9. USGI Medical Demonstrates First System for Gastrotomy Closure in NOTES
10. Job-related stress: NIST demonstrates fatigue effects in silicon
11. Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resistant Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... August 28, 2014 The ability for ... culture that will allow individuals to perform at the ... important for employers looking to compete in this post–recession ... embracing this trend, as the sector increasingly focuses on ... company, which will have real results on the organization's ...
(Date:8/28/2014)... ATLANTA , Aug. 28, 2014   SunTrust ... of three industry veterans to its equity research ... "Our ongoing expansion in equity research demonstrates ... with unique insights to enhance their investment decision ... Equities at STRH.  "We continue to make significant ...
(Date:8/28/2014)... Calif. , Aug. 28, 2014  Armetheon, ... on developing novel mid- to late-stage cardiovascular drug ... million in its first round of financing. The ... Investments and Hercules Bioventures with participation from investors ... and pharmaceutical executive, Dr. Larry Hsu , ...
(Date:8/28/2014)... 27, 2014 Scientists, researchers, and technologists ... SPIE Laser Damage 2014 symposium. Marking its 46th ... lasers will run 14-17 September. The event is sponsored ... photonics . , The premier conference for basic and ... to optical materials will engage researchers and engineers from ...
Breaking Biology Technology:Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 3
... flu is already tough, but it has become even harder in ... two antiviral drugs don,t slow it down anymore. Reporting their ... and Brigham Young move closer to understanding why not, and how ... changes. The two drugs, amantadine and rimantadine, are no longer ...
... Biosystems announced the release of its second generation of ... the company,s popular in vivo delivery product line: PEG-Liposome ... compatible for in vivo transfection of other negatively charged ... also offers custom encapsulation of target molecules into PEG-liposome ...
... Oct. 21 Sermo ( http://www.sermo.com ), the largest ... Report titled, " Physician Participation in the ESA REMS ... rates in the FDA-required Erythropoiesis-Stimulating Agents (ESAs) risk evaluation ... the results, 83% of Hematologists/Oncologists view the ESA REMS ...
Cached Biology Technology:Putting a bull's-eye on the flu: Detailing influenza's structure for drug targeting 2PEG-Liposome siRNA In Vivo Transfection Kit From Altogen Biosystems 2Sermo Report Indicates Possible Decline in Prescribing of Erythropoiesis-Stimulating Agents 2
(Date:8/29/2014)... Bend them, stretch them, twist them, fold them: modern ... extraordinary technological potential, whether as artificial skin or electronic ... use remains a challenge but a new way of ... could be a game-changer. , Previous success in ... on the use of precious gold and silver nanowires. ...
(Date:8/28/2014)... expansion of marine protected areas is needed to protect ... to investigators from the Wildlife Conservation Society and other ... saving the largest numbers of species, often at the ... ecological functions. , Many vital ecological functions ... also are food for millions of people. This ...
(Date:8/28/2014)... the University of Minnesota have developed an animal research ... for muscle regeneration research as well as studies of ... research is published in the current edition of the ... treatment for FSHD, which is thought by many to ... is an unusual genetic disorder because, unlike most genetic ...
Breaking Biology News(10 mins):Copper shines as flexible conductor 2Study finds marine protected areas inadequate for protecting fish and ocean ecology 2UMN researchers find animal model for understudied type of muscular dystrophy 2
... There are few things more irritating than a fly ... to the problem. They hang up a bunch of Roridula ... leaf,s hairs, the hapless pest is soon trapped by the ... story. Each R. gorgonias plant is home to a population ...
... model for studying the genetics of Angelman syndrome, a ... in one out of 15,000 births, has been developed ... Their research demonstrates that when a particular fruit ... behavioral dysfunctions similar to those experienced by humans whose ...
... Say the word "biofuels" and most people think of ... technology called gasification that,s getting a new look from ... and Iowa State University. By combining gasification with ... from a wide range of biomass, including distiller,s grain ...
Cached Biology News:Nothing stops an expert in the art of living 2Model for angelman syndrome developed by University of Texas at Austin biologists 2Turning waste material into ethanol 2
... is a serine/threonine phosphatase isolated from human ... the heterodimer of 60kDa (A) and 36kDa ... dephosphorylate the a-subunit of phosphorylase kinase. With ... substrate specificity and may play a regulatory ...
... Analysis Note: Assays in Tris buffer, ... in the glycine buffer system. Assays in ... 5X that of the glycine buffer system. ... powder containing Tris-citrate buffer salts Preparation Unit ...
... The ATP Monitoring Kit ... with high sensitivity and a ... bioluminescence technique, the assay measures ... animal cells over a concentration ...
... condenses and traps a wide variety of solvent vapors ... glass condensation flask (GCF400) allows for the collection of ... Rapid cooling time minimizes waiting period., Ultra ... solvents , Digital Display ...
Biology Products: